83019-89-0

Basic information

• Product Name: N-(2-aminoethyl)methanesulfonamide
• Synonyms: N-(2-AMINOETHYL)METHANESULFONAMIDE HCL;N-(2-aminoethyl)methanesulfonamide(SALTDATA: HCl)
• CAS NO: 83019-89-0
• Molecular Formula: C₃H₁₀N₂O₂S
• Molecular Weight: 138
• Mol File: 83019-89-0.mol

Chemical Properties

• Boiling Point: 256.1 °C at 760 mmHg
• Flash Point: 108.7 °C
• Appearance: /
• Density: 1.238 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• PKA: 7.61±0.40(Predicted)
• CAS DataBase Reference: N-(2-aminoethyl)methanesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-aminoethyl)methanesulfonamide(83019-89-0)
• EPA Substance Registry System: N-(2-aminoethyl)methanesulfonamide(83019-89-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 83019-89-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-(2-aminoethyl)methanesulfonamide is utilized as a pharmaceutical intermediate for the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a key component in the development of new drugs.
Used in Organic Chemistry:
In the field of organic chemistry, N-(2-aminoethyl)methanesulfonamide serves as a reagent in various chemical reactions, facilitating the synthesis of complex organic compounds.
Used in Medical Research:
Due to its potential anti-inflammatory and antioxidant properties, N-(2-aminoethyl)methanesulfonamide is being investigated for its possible use in the treatment of a range of diseases, where its ability to modulate biological processes could offer therapeutic benefits.

Upstream product

• 1190044-23-5 tert-butyl {2-[(methylsulfonyl)amino]ethyl}carbamate 
• 75-75-2 methanesulfonic acid 
• 107-15-3 ethylenediamine 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 53672-07-4 N-{2-[2-Hydroxy-3-(4-hydroxy-phenoxy)-propylamino]-ethyl}-methanesulfonamide 
• 769194-74-3 6-(2-bromo-phenyl)-2-methylsulfanyl-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-methanesulfonylamino-ethyl)-amide 
• 202196-91-6 2-((5-(4-(4-Benzyloxy-phenylamino)-quinazolin-6-yl)-furan-2-ylmethyl)-amino)-ethanesulphonic acid methylamide 
• 72080-83-2 2-benzyloxycarbonylaminoethylamine 
• 1260000-47-2 C₂₉H₃₉N₅O₅S 
• 1392831-96-7 [(η⁶-biphenyl)Ru(N-(2-aminoethyl)methylsulfonamide(1-))Cl] 
• 865756-05-4 6-(2,6-dichloro-phenyl)-2-methylsulfanylpyrido[2,3-d]pyrimidine-7-carboxylic acid (2-methanesulfonylamino-ethyl)-amide 

Relevant articles and documents

NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF

It is intended to provide a novel compound having high antitumor activity and low toxicity to normal cells. The present invention provides a pyridone carboxylic acid derivative represented by the following formula (1) or a salt thereof wherein R1 represents a hydrogen atom, a halogen atom or the like; R2 represents a hydrogen atom, a halogen atom or the like; R3 to R6 each represent a hydrogen atom or the like; R7 represents a hydrogen atom or the like; R8 represents a hydrogen atom, a halogen atom, the following formula (a) (wherein Ra1 and Ra2 each represent a hydrogen atom, a hydroxy group, an optionally substituted lower alkyl group or the like) or the like, or R7 and R8 together represent —N—OR10 (wherein R10 represents a hydrogen atom, an optionally substituted lower alkyl group, or an aralkyl group), or R7 and R8 form an optionally substituted 4- to 6-membered saturated hetero ring together with the adjacent carbon atom, or the like; R9 represents a hydrogen atom or the like; X represents a nitrogen atom or the like; and Y represents a nitrogen atom or the like.

Synthesis and biological evaluation of ethacrynic acid derivatives bearing sulfonamides as potent anti-cancer agents

A series of ethacrynic acid (2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid) (EA, Edecrin) containing sulfonamides linked via three types of linkers namely 1,2-ethylenediamine, piperazine and 4-aminopiperidine was synthesized and subsequently evaluated in vitro against HL60 and HCT116 cancer cell lines. All the EA analogs, excluding 6a and 6c, showed anti-proliferative activity with IC50s in the micromolar range (less than 4 uM). Three derivatives 6b, 7b and 7e were selected for their interesting dual activity on HL60 cell line in order to be further evaluated against a panel of cancer cell lines (HCT116, A549, MCF7, PC3, U87-MG and SKOV3) as well as on MRC5 as a normal cell line. These compounds displayed IC50 values in nanomolar range against A549, MCF7, PC3 and HCT116 cell lines, deducing the discovery that piperazine or 4-aminopiperidine is the linker's best choice to develop EA analogs with highly potent anti-proliferative activities own up to 24 nM. Besides, in terms of selectivity, those linkers are more suitable offering safety ratios of up to 63.8.

New thiadiazole derivatives

The present invention relates to thiadiazole derivatives of formula (I), to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent agonists of S1P1 receptors and thus, they are useful in the treatment, prevention or suppression of diseases and disorders known to be susceptible to improvement by sphingosine-1-phosphate receptors agonists (S1P1), such as autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic-related disorders, pain, neurological diseases, viral and infectious diseases.

NEW THIADIAZOLE DERIVATIVES

The present invention relates to thiadiazole derivatives of formula (I), to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent agonists of S1P1 receptors and thus, they are useful In the treatment, prevention or suppression of diseases and disorders known to be susceptible to improvement by sphingosine-1-phosphate receptors agonists (S1P1), such as autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic-related disorders, pain, neurological diseases, viral and infectious diseases.

PH-Regulated transfer hydrogenation of quinoxalines with a Cp*Ir-diamine catalyst in aqueous media

The combination of [Cp*IrCl2]2 with N-(2-aminoethyl)-4-(trifluoromethyl)benzenesulfonamide constitutes an efficient catalyst for selective transfer hydrogenation of a variety of quinoxalines in water with HCOONa as the hydrogen source, affording the corresponding tetrahydroquinoxalines in good to excellent yields. The catalyst is air-stable, and the reduction could be performed without nitrogen protection. The aqueous phase reduction is shown to be highly pH-dependent, with acidic pH leading to better results. There exits a pH window for optimum rate, and the use of HOAc/NaOAc buffer solution is essential for maintaining a stable pH during the reaction.

FATTY ACID ACETYLATED SALICYLATES AND THEIR USES

The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.

Chemoselective conjugate reduction of α,β-unsaturated ketones catalyzed by rhodium amido complexes in aqueous media

Although a notable feature of Noyori's Ru-TsDPEN complex is that the transfer hydrogenation reaction is highly chemoselective for the C-O functional group and tolerant of alkenes, our early report indicated that the chemoselectivity could be switched from C-O to C-C bonds in the transfer hydrogenation of activated α,β-unsaturated ketones. Now we have found that a variety of α,β-unsaturated ketones, even without other electron-withdrawing functional groups, could be reduced on the alkenic double bonds with high selectivities employing amido-rhodium hydride complex in aqueous media, and up to 100% chemoselectivity has been achieved. It is notable that the chemoselectivity was improved significantly on going from organic solvent to water. Moreover, a 1,4-addition mechanism has been proposed on the basis of the corresponding experimental details and computational analysis.